Zenas BioPharma Total Long Term Liabilities 2023-2025 | ZBIO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Zenas BioPharma total long term liabilities from 2023 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Zenas BioPharma total long term liabilities from 2023 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$213.3B
Amgen (AMGN)	$158.5B
Gilead Sciences (GILD)	$134.6B
Vertex Pharmaceuticals (VRTX)	$118.1B
Bristol Myers Squibb (BMY)	$96.4B
CSL (CSLLY)	$81.2B
GSK (GSK)	$74.3B
Regeneron Pharmaceuticals (REGN)	$58.6B
Alnylam Pharmaceuticals (ALNY)	$41.8B
Argenex SE (ARGX)	$34.6B
BioNTech SE (BNTX)	$26.4B
Royalty Pharma (RPRX)	$20B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18.3B
Illumina (ILMN)	$15.2B
Genmab (GNMSF)	$14.3B
Genmab (GMAB)	$14B
Incyte (INCY)	$13.1B
Exelixis (EXEL)	$12.1B
Moderna (MRNA)	$12.1B
BioMarin Pharmaceutical (BMRN)	$11B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.4B
Exact Sciences (EXAS)	$9.5B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$8.2B
Roivant Sciences (ROIV)	$7.8B
Legend Biotech (LEGN)	$7.6B